SCHEMBL2415649

SCHEMBL2415649

Nc1ccc(N2CC(O)CC2C(=O)O)nc1N1CCCC1CO

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.39
OGFRL1 Q5TC84 1/20 0.39
CCNE2 O96020 1/20 0.38
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
GAA P10253 1/20 0.38
PAK4 O96013 1/20 0.37
ADORA2A P29274 6/20 0.36
ADORA1 P30542 6/20 0.36
ADORA3 P0DMS8 5/20 0.36
CHUK O15111 2/20 0.36
SCN9A Q15858 2/20 0.35
FPR2 P25090 1/20 0.34
ADORA2B P29275 1/20 0.32
BCL6 P41182 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2415211 0.88 GAA (0.43) OGFRL1GAASCN9A
SCHEMBL2421089 0.88 KMT2A (0.38) PDE10AOGFRL1CCNE2CDK4CCND1
SCHEMBL2411637 0.87 CCNE2 (0.42) PDE10AOGFRL1CCNE2CDK4CCND1
SCHEMBL2414751 0.87 PDE10A (0.45) PDE10ACCNE2CDK4CCND1CCNE1
SCHEMBL2417287 0.85 KMT2A (0.42) PDE10AOGFRL1CCNE2CDK4CCND1
SCHEMBL2415998 0.82 CCNE2 (0.40) PDE10ACCNE2CDK4CCND1CCNE1
SCHEMBL2412675 0.82 CHUK (0.47) PDE10ACCNE2CDK4CCND1CCNE1
SCHEMBL2415857 0.82 PDE10A (0.38) PDE10ACCNE2CDK4CCND1CCNE1
SCHEMBL2413721 0.82 GAA (0.42) OGFRL1GAASCN9A
SCHEMBL2410500 0.81 GAA (0.38) OGFRL1GAASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1312606-B1 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres OREAL (FR) 2011-09-21 EP claimed
CN-1250192-C 2,5-diaminopyridine oxidation color display alkali for dyeing keratin fibre OREAL (FR) 2006-04-12 CN claimed
US-6837908-B2 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres L'OREAL S.A. (FR) 2005-01-04 US claimed
US-20030163876-A1 Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres L'OREAL S.A. (FR) 2003-09-04 US claimed
CN-1425365-A 2,5-diaminopyridine oxidation color display alkali for dyeing keratin fibre OREAL (FR) 2003-06-25 CN claimed
EP-1312606-A1 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres L'OREAL (FR) 2003-05-21 EP claimed
EP-1312606-B1 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres OREAL (FR) 2011-09-21 EP disclosed
CN-1250192-C 2,5-diaminopyridine oxidation color display alkali for dyeing keratin fibre OREAL (FR) 2006-04-12 CN disclosed
US-6837908-B2 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres L'OREAL S.A. (FR) 2005-01-04 US disclosed
US-20030163876-A1 Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres L'OREAL S.A. (FR) 2003-09-04 US disclosed
CN-1425365-A 2,5-diaminopyridine oxidation color display alkali for dyeing keratin fibre OREAL (FR) 2003-06-25 CN disclosed
EP-1312606-A1 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres L'OREAL (FR) 2003-05-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030163876-A1 Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres KRT18, DPYD, DSP PDE10A 3263/4885OGFRL1 2645/4885CCNE2 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.